Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Margaret Ann Shipp, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA161026 (SHIPP, MARGARET A) Aug 22, 2011 - Jun 30, 2021
    NIH/NCI
    Targetable Immune Evasion Pathways in Hodgkin Lymphoma
    Role: Principal Investigator
  2. P01CA092625 (SHIPP, MARGARET A) Aug 1, 2009 - Jun 30, 2013
    NIH/NCI
    PROGRAM PROJECT GRANT: Molecular Targets of Germinal Center B-Cell Lymphomas
    Role: Principal Investigator
  3. R01CA076286 (SHIPP, MARGARET A) Jul 17, 1998 - Apr 30, 2004
    NIH/NCI
    STROMELYSIN 3 AND THE TUMOR MICROENVIRONMENT
    Role: Principal Investigator
  4. P01CA066996 (EBERT, BENJAMIN LEVINE) Apr 25, 1997 - Mar 31, 2008
    NIH/NCI
    Development of Novel Therapeutic Strategies in Human Leukemias
    Role: Co-Principal Investigator
  5. P30CA006516 (GLIMCHER, LAURIE HOLLIS) Mar 10, 1997 - Sep 29, 2012
    NIH/NCI
    Dana-Farber/Harvard Cancer Center
    Role: Co-Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Griffin GK, Weirather JL, Roemer M, Lipschitz M, Kelley A, Chen PH, Gusenleitner D, Jeter E, Gjini E, Chapuy B, Rosenthal M, Xu J, Chen BJ, Sohani A, Lovitch SB, Abramson J, Ishizuka JJ, Kim AI, Jacobson CA, LaCasce AS, Fletcher CDM, Neuberg D, Freeman GJ, Hodi FS, Wright K, Ligon AH, Jacobsen ED, Armand P, Shipp MA, Rodig SJ. Spatial Signatures Identify Immune Escape via PD-1 as a Defining Feature of T-cell/Histiocyte-rich Large B-cell Lymphoma. Blood. 2020 Sep 01. PMID: 32871584.
    Citations:    Fields:    
  2. Cader FZ, Hu X, Goh WL, Wienand K, Ouyang J, Mandato E, Redd R, Lawton LN, Chen PH, Weirather JL, Schackmann RCJ, Li B, Ma W, Armand P, Rodig SJ, Neuberg D, Liu XS, Shipp MA. A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. Nat Med. 2020 09; 26(9):1468-1479. PMID: 32778827.
    Citations:    Fields:    
  3. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126. PMID: 31917843.
    Citations:    Fields:    
  4. Zinzani PL, Chen R, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Nahar A, Balakumaran A, Moskowitz CH. Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma. 2020 04; 61(4):950-954. PMID: 31905294.
    Citations: 1     Fields:    
  5. Chapuy B, Stewart C, Dunford AJ, Kim J, Wienand K, Kamburov A, Griffin GK, Chen PH, Lako A, Redd RA, Cote CM, Ducar MD, Thorner AR, Rodig SJ, Getz G, Shipp MA. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood. 2019 12 26; 134(26):2369-2382. PMID: 31697821.
    Citations: 4     Fields:    Translation:Humans
  6. Wienand K, Chapuy B, Stewart C, Dunford AJ, Wu D, Kim J, Kamburov A, Wood TR, Cader FZ, Ducar MD, Thorner AR, Nag A, Heubeck AT, Buonopane MJ, Redd RA, Bojarczuk K, Lawton LN, Armand P, Rodig SJ, Fromm JR, Getz G, Shipp MA. Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. Blood Adv. 2019 12 10; 3(23):4065-4080. PMID: 31816062.
    Citations: 2     Fields:    Translation:HumansCells
  7. Patel SS, Weirather JL, Lipschitz M, Lako A, Chen PH, Griffin GK, Armand P, Shipp MA, Rodig SJ. The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative. Blood. 2019 12 05; 134(23):2059-2069. PMID: 31697809.
    Citations: 4     Fields:    Translation:HumansCells
  8. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL. Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. J Clin Oncol. 2019 12 01; 37(34):3291-3299. PMID: 31609651.
    Citations: 15     Fields:    Translation:HumansCTClinical Trials
  9. Chen L, Ouyang J, Wienand K, Bojarczuk K, Hao Y, Chapuy B, Neuberg D, Juszczynski P, Lawton LN, Rodig SJ, Monti S, Shipp MA. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica. 2020 05; 105(5):1361-1368. PMID: 31471373.
    Citations: 2     Fields:    
  10. Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019 10 03; 134(14):1144-1153. PMID: 31409671.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  11. Ramchandren R, Domingo-Domènech E, Rueda A, Trnený M, Feldman TA, Lee HJ, Provencio M, Sillaber C, Cohen JB, Savage KJ, Willenbacher W, Ligon AH, Ouyang J, Redd R, Rodig SJ, Shipp MA, Sacchi M, Sumbul A, Armand P, Ansell SM. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. J Clin Oncol. 2019 08 10; 37(23):1997-2007. PMID: 31112476.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  12. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29. PMID: 30952672.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  13. Ansell SM, Minnema MC, Johnson P, Timmerman JM, Armand P, Shipp MA, Rodig SJ, Ligon AH, Roemer MGM, Reddy N, Cohen JB, Assouline S, Poon M, Sharma M, Kato K, Samakoglu S, Sumbul A, Grigg A. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study. J Clin Oncol. 2019 02 20; 37(6):481-489. PMID: 30620669.
    Citations: 20     Fields:    Translation:HumansCellsCTClinical Trials
  14. Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, Stachura J, Letai A, Lawton LN, Chapuy B, Shipp MA. Targeted inhibition of PI3Ka/d is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019 01 03; 133(1):70-80. PMID: 30322870.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  15. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1292. PMID: 29955181.
    Citations:    Fields:    
  16. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 Aug; 24(8):1290-1291. PMID: 29955182.
    Citations: 4     Fields:    
  17. Cader FZ, Schackmann RCJ, Hu X, Wienand K, Redd R, Chapuy B, Ouyang J, Paul N, Gjini E, Lipschitz M, Armand P, Wu D, Fromm JR, Neuberg D, Liu XS, Rodig SJ, Shipp MA. Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment. Blood. 2018 08 23; 132(8):825-836. PMID: 29880615.
    Citations: 13     Fields:    Translation:HumansCells
  18. Neuberg DS, Rodig SJ, Shipp MA. Reply to Z. Wu et al. J Clin Oncol. 2018 09 01; 36(25):2657. PMID: 29847290.
    Citations:    Fields:    Translation:Humans
  19. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Pedamallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018 05; 24(5):679-690. PMID: 29713087.
    Citations: 129     Fields:    Translation:Humans
  20. Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018 05 10; 36(14):1428-1439. PMID: 29584546.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  21. Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol. 2018 04 01; 36(10):942-950. PMID: 29394125.
    Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
  22. Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):310-316. PMID: 29222272.
    Citations: 4     Fields:    Translation:HumansCells
  23. Liu WR, Shipp MA. Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma. Blood. 2017 11 23; 130(21):2265-2270. PMID: 29167175.
    Citations: 10     Fields:    Translation:HumansCells
  24. Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ. Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. Blood. 2017 11 30; 130(22):2420-2430. PMID: 28893733.
    Citations: 41     Fields:    Translation:HumansCells
  25. Zinzani PL, Ribrag V, Moskowitz CH, Michot JM, Kuruvilla J, Balakumaran A, Zhang Y, Chlosta S, Shipp MA, Armand P. Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. Blood. 2017 07 20; 130(3):267-270. PMID: 28490569.
    Citations: 45     Fields:    Translation:HumansCTClinical Trials
  26. Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G, Zhou J, Piesche M, Dranoff G, Rodig S, Shipp M, Hodi FS. Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunol Res. 2017 06; 5(6):446-454. PMID: 28473314.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  27. Chen R, Zinzani PL, Fanale MA, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Zhang Y, Ricart AD, Balakumaran A, Moskowitz CH. Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J Clin Oncol. 2017 Jul 01; 35(19):2125-2132. PMID: 28441111.
    Citations: 154     Fields:    Translation:HumansCTClinical Trials
  28. Nayak L, Iwamoto FM, LaCasce A, Mukundan S, Roemer MGM, Chapuy B, Armand P, Rodig SJ, Shipp MA. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma. Blood. 2017 06 08; 129(23):3071-3073. PMID: 28356247.
    Citations: 57     Fields:    Translation:Humans
  29. Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90. PMID: 28018601.
    Citations: 5     Fields:    
  30. Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, Snyder ES, Ricart AD, Balakumaran A, Rose S, Moskowitz CH. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure. J Clin Oncol. 2016 11 01; 34(31):3733-3739. PMID: 27354476.
    Citations: 155     Fields:    Translation:HumansCTClinical Trials
  31. Norberg E, Lako A, Chen PH, Stanley IA, Zhou F, Ficarro SB, Chapuy B, Chen L, Rodig S, Shin D, Choi DW, Lee S, Shipp MA, Marto JA, Danial NN. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 2017 02; 24(2):251-262. PMID: 27768122.
    Citations: 5     Fields:    Translation:HumansCells
  32. Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ. Classical Hodgkin Lymphoma with Reduced ß2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. Cancer Immunol Res. 2016 11; 4(11):910-916. PMID: 27737878.
    Citations: 38     Fields:    Translation:HumansCells
  33. Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep; 17(9):1283-94. PMID: 27451390.
    Citations: 195     Fields:    Translation:HumansCTClinical Trials
  34. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. PMID: 27479034.
    Citations: 16     Fields:    
  35. Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016 08 10; 34(23):2698-704. PMID: 27269947.
    Citations: 219     Fields:    Translation:HumansCellsCTClinical Trials
  36. Houot R, Gaulard P, Schreiber R, Mellman I, Lambotte O, Coulie PG, Fest T, Korman A, Levy R, Shipp M, Tarte K, Kohrt H, Marabelle A, Ansell S, Watier H, van Elsas A, Balakumaran A, Arce Vargas F, Quezada SA, Salles G, Olive D. Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. Oncoimmunology. 2016 Jul; 5(7):e1186323. PMID: 27622041.
    Citations: 2     
  37. Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA, Kobayashi KS. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016 May 24; 113(21):5999-6004. PMID: 27162338.
    Citations: 36     Fields:    Translation:HumansCells
  38. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. PMID: 27070704.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  39. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol. 2016 08 10; 34(23):2690-7. PMID: 27069084.
    Citations: 158     Fields:    Translation:HumansCells
  40. Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, Lee L, Viswanathan A, Horowitz N, Neuberg D, Crum CP, Lindeman NL, Kuo F, Ligon AH, Freeman GJ, Hodi FS, Shipp MA, Rodig SJ. Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva. JAMA Oncol. 2016 Apr; 2(4):518-22. PMID: 26913631.
    Citations: 37     Fields:    Translation:Humans
  41. Chapuy B, Cheng H, Watahiki A, Ducar MD, Tan Y, Chen L, Roemer MG, Ouyang J, Christie AL, Zhang L, Gusenleitner D, Abo RP, Farinha P, von Bonin F, Thorner AR, Sun HH, Gascoyne RD, Pinkus GS, van Hummelen P, Wulf GG, Aster JC, Weinstock DM, Monti S, Rodig SJ, Wang Y, Shipp MA. Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood. 2016 05 05; 127(18):2203-13. PMID: 26773040.
    Citations: 14     Fields:    Translation:HumansAnimalsCells
  42. Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, Dunford AJ, Meredith DM, Thorner AR, Jordanova ES, Liu G, Feuerhake F, Ducar MD, Illerhaus G, Gusenleitner D, Linden EA, Sun HH, Homer H, Aono M, Pinkus GS, Ligon AH, Ligon KL, Ferry JA, Freeman GJ, van Hummelen P, Golub TR, Getz G, Rodig SJ, de Jong D, Monti S, Shipp MA. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016 Feb 18; 127(7):869-81. PMID: 26702065.
    Citations: 78     Fields:    Translation:Humans
  43. Karreth FA, Reschke M, Ruocco A, Ng C, Chapuy B, Léopold V, Sjoberg M, Keane TM, Verma A, Ala U, Tay Y, Wu D, Seitzer N, Velasco-Herrera Mdel C, Bothmer A, Fung J, Langellotto F, Rodig SJ, Elemento O, Shipp MA, Adams DJ, Chiarle R, Pandolfi PP. The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivo. Cell. 2015 Apr 09; 161(2):319-32. PMID: 25843629.
    Citations: 91     Fields:    Translation:HumansAnimalsCells
  44. Weinstock DM, Dalla-Favera R, Gascoyne RD, Leonard JP, Levy R, Lossos IS, Melnick AM, Nowakowski GS, Press OW, Savage KJ, Shipp MA, Staudt LM. A roadmap for discovery and translation in lymphoma. Blood. 2015 Mar 26; 125(13):2175-7. PMID: 25814490.
    Citations: 8     Fields:    Translation:Humans
  45. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22; 372(4):311-9. PMID: 25482239.
    Citations: 967     Fields:    Translation:HumansCellsCTClinical Trials
  46. Shi M, Roemer MG, Chapuy B, Liao X, Sun H, Pinkus GS, Shipp MA, Freeman GJ, Rodig SJ. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain. Am J Surg Pathol. 2014 Dec; 38(12):1715-23. PMID: 25025450.
    Citations: 37     Fields:    Translation:Humans
  47. Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, Neuberg D, Sohani AR, Shipp MA, Monti S, Rodig SJ. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. J Mol Diagn. 2015 Jan; 17(1):19-30. PMID: 25468432.
    Citations: 3     Fields:    Translation:Humans
  48. Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014 May 15; 20(10):2674-83. PMID: 24610827.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  49. Croci DO, Cerliani JP, Dalotto-Moreno T, Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA, Caramelo JJ, García-Vallejo JJ, Ouyang J, Mesri EA, Junttila MR, Bais C, Shipp MA, Salatino M, Rabinovich GA. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell. 2014 Feb 13; 156(4):744-58. PMID: 24529377.
    Citations: 126     Fields:    Translation:HumansAnimalsCells
  50. Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, Reichert E, Kung AL, Rodig SJ, Young RA, Shipp MA, Bradner JE. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013 Dec 09; 24(6):777-90. PMID: 24332044.
    Citations: 243     Fields:    Translation:HumansCells
  51. Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA. SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell. 2013 Jun 10; 23(6):826-38. PMID: 23764004.
    Citations: 57     Fields:    Translation:HumansCells
  52. Chen BJ, Chapuy B, Ouyang J, Sun HH, Roemer MG, Xu ML, Yu H, Fletcher CD, Freeman GJ, Shipp MA, Rodig SJ. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013 Jul 01; 19(13):3462-73. PMID: 23674495.
    Citations: 210     Fields:    Translation:HumansCells
  53. Ouyang J, Plütschow A, Pogge von Strandmann E, Reiners KS, Ponader S, Rabinovich GA, Neuberg D, Engert A, Shipp MA. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. Blood. 2013 Apr 25; 121(17):3431-3. PMID: 23444403.
    Citations: 27     Fields:    Translation:Humans
  54. Yan Q, Xu R, Zhu L, Cheng X, Wang Z, Manis J, Shipp MA. BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8. Mol Cell Biol. 2013 Feb; 33(4):845-57. PMID: 23230272.
    Citations: 29     Fields:    Translation:HumansCells
  55. Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res. 2013 Jan 01; 73(1):86-96. PMID: 23108139.
    Citations: 48     Fields:    Translation:HumansCells
  56. Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, Polak K, Tondera D, Gounarides J, Yin H, Zhou F, Green MR, Chen L, Monti S, Marto JA, Shipp MA, Danial NN. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012 Oct 16; 22(4):547-60. PMID: 23079663.
    Citations: 123     Fields:    Translation:HumansCells
  57. Croci DO, Salatino M, Rubinstein N, Cerliani JP, Cavallin LE, Leung HJ, Ouyang J, Ilarregui JM, Toscano MA, Domaica CI, Croci MC, Shipp MA, Mesri EA, Albini A, Rabinovich GA. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med. 2012 Oct 22; 209(11):1985-2000. PMID: 23027923.
    Citations: 56     Fields:    Translation:HumansAnimalsCells
  58. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Habermann TM, Getz G, Kung AL, Golub TR, Shipp MA. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012 Sep 11; 22(3):359-72. PMID: 22975378.
    Citations: 66     Fields:    Translation:Humans
  59. Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012; 7(4):e33813. PMID: 22511926.
    Citations: 39     Fields:    Translation:Humans
  60. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, Cruz-Gordillo P, Knoechel B, Asmann YW, Slager SL, Novak AJ, Dogan A, Ansell SM, Link BK, Zou L, Gould J, Saksena G, Stransky N, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Hernández-Lemus E, Schwarz-Cruz y Celis A, Imaz-Rosshandler I, Ojesina AI, Jung J, Pedamallu CS, Lander ES, Habermann TM, Cerhan JR, Shipp MA, Getz G, Golub TR. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3879-84. PMID: 22343534.
    Citations: 339     Fields:    Translation:HumansCells
  61. Green MR, Rodig S, Juszczynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res. 2012 Mar 15; 18(6):1611-8. PMID: 22271878.
    Citations: 168     Fields:    Translation:HumansCells
  62. Duan S, Cermak L, Pagan JK, Rossi M, Martinengo C, di Celle PF, Chapuy B, Shipp M, Chiarle R, Pagano M. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012 Jan 05; 481(7379):90-3. PMID: 22113614.
    Citations: 96     Fields:    Translation:HumansAnimalsCells
  63. Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA, Kutok JL, Drapkin RI, Rodig SJ. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol. 2011 Oct; 35(10):1531-9. PMID: 21921781.
    Citations: 4     Fields:    Translation:HumansCells
  64. Ouyang J, Juszczynski P, Rodig SJ, Green MR, O'Donnell E, Currie T, Armant M, Takeyama K, Monti S, Rabinovich GA, Ritz J, Kutok JL, Shipp MA. Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 2011 Apr 21; 117(16):4315-22. PMID: 21300977.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
  65. Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. Proc Natl Acad Sci U S A. 2011 Feb 15; 108(7):2873-8. PMID: 21282644.
    Citations: 25     Fields:    Translation:HumansAnimalsCells
  66. Rodig SJ, Kutok JL, Paterson JC, Nitta H, Zhang W, Chapuy B, Tumwine LK, Montes-Moreno S, Agostinelli C, Johnson NA, Ben-Neriah S, Farinha P, Shipp MA, Piris MA, Grogan TM, Pileri SA, Gascoyne RD, Marafioti T. The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas. Haematologica. 2010 Dec; 95(12):2056-62. PMID: 20823132.
    Citations: 2     Fields:    Translation:HumansCells
  67. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010 Oct 28; 116(17):3268-77. PMID: 20628145.
    Citations: 323     Fields:    Translation:HumansCells
  68. Juszczynski P, Rodig SJ, Ouyang J, O'Donnell E, Takeyama K, Mlynarski W, Mycko K, Szczepanski T, Gaworczyk A, Krivtsov A, Faber J, Sinha AU, Rabinovich GA, Armstrong SA, Kutok JL, Shipp MA. MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res. 2010 Apr 01; 16(7):2122-30. PMID: 20332322.
    Citations: 9     Fields:    Translation:HumansCells
  69. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 01; 115(13):2578-85. PMID: 19965662.
    Citations: 264     Fields:    Translation:HumansCTClinical Trials
  70. Juszczynski P, Chen L, O'Donnell E, Polo JM, Ranuncolo SM, Dalla-Favera R, Melnick A, Shipp MA. BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood. 2009 Dec 17; 114(26):5315-21. PMID: 19855081.
    Citations: 28     Fields:    Translation:HumansCells
  71. Yan Q, Dutt S, Xu R, Graves K, Juszczynski P, Manis JP, Shipp MA. BBAP monoubiquitylates histone H4 at lysine 91 and selectively modulates the DNA damage response. Mol Cell. 2009 Oct 09; 36(1):110-20. PMID: 19818714.
    Citations: 50     Fields:    Translation:HumansCells
  72. Wu D, Dutra B, Lindeman N, Takahashi H, Takeyama K, Harris NL, Pinkus GS, Longtine J, Shipp M, Kutok JL. No evidence for the JAK2 (V617F) or JAK2 exon 12 mutations in primary mediastinal large B-cell lymphoma. Diagn Mol Pathol. 2009 Sep; 18(3):144-9. PMID: 19704259.
    Citations: 4     Fields:    Translation:Humans
  73. Gobert RP, van den Eijnden M, Szyndralewiez C, Jorand-Lebrun C, Swinnen D, Chen L, Gillieron C, Pixley F, Juillard P, Gerber P, Johnson-Léger C, Halazy S, Camps M, Bombrun A, Shipp M, Vitte PA, Ardissone V, Ferrandi C, Perrin D, Rommel C, Hooft van Huijsduijnen R. GLEPP1/protein-tyrosine phosphatase phi inhibitors block chemotaxis in vitro and in vivo and improve murine ulcerative colitis. J Biol Chem. 2009 Apr 24; 284(17):11385-95. PMID: 19233845.
    Citations: 4     Fields:    Translation:AnimalsCells
  74. Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, Takeyama K, Shipp MA. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. Br J Haematol. 2009 Feb; 144(3):358-66. PMID: 19036086.
    Citations: 15     Fields:    Translation:HumansCells
  75. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res. 2008 Jun 01; 14(11):3338-44. PMID: 18519761.
    Citations: 22     Fields:    Translation:HumansCells
  76. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood. 2008 Feb 15; 111(4):2230-7. PMID: 18006696.
    Citations: 127     Fields:    Translation:HumansCells
  77. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J, Chen W, Kutok JL, Rabinovich GA, Shipp MA. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A. 2007 Aug 07; 104(32):13134-9. PMID: 17670934.
    Citations: 94     Fields:    Translation:HumansCells
  78. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007 Aug; 12(2):171-85. PMID: 17692808.
    Citations: 216     Fields:    Translation:HumansCells
  79. Takeyama K, Monti S, Manis JP, Dal Cin P, Getz G, Beroukhim R, Dutt S, Aster JC, Alt FW, Golub TR, Shipp MA. Integrative analysis reveals 53BP1 copy loss and decreased expression in a subset of human diffuse large B-cell lymphomas. Oncogene. 2008 Jan 10; 27(3):318-22. PMID: 17637749.
    Citations: 12     Fields:    Translation:HumansCells
  80. Parekh S, Polo JM, Shaknovich R, Juszczynski P, Lev P, Ranuncolo SM, Yin Y, Klein U, Cattoretti G, Dalla Favera R, Shipp MA, Melnick A. BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 2007 Sep 15; 110(6):2067-74. PMID: 17545502.
    Citations: 50     Fields:    Translation:HumansCells
  81. Peterson BA, Johnson J, Shipp MA, Barcos M, Gockerman JP, Canellos GP. High dose CHOP: a phase II study of initial treatment in aggressive non-Hodgkin lymphoma. Cancer and Leukemia Group B 9351. Leuk Lymphoma. 2007 May; 48(5):870-80. PMID: 17487729.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  82. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007 May 01; 25(13):1741-6. PMID: 17389337.
    Citations: 70     Fields:    Translation:HumansCTClinical Trials
  83. Polo JM, Juszczynski P, Monti S, Cerchietti L, Ye K, Greally JM, Shipp M, Melnick A. Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proc Natl Acad Sci U S A. 2007 Feb 27; 104(9):3207-12. PMID: 17360630.
    Citations: 55     Fields:    Translation:HumansCells
  84. Rodig SJ, Savage KJ, LaCasce AS, Weng AP, Harris NL, Shipp MA, Hsi ED, Gascoyne RD, Kutok JL. Expression of TRAF1 and nuclear c-Rel distinguishes primary mediastinal large cell lymphoma from other types of diffuse large B-cell lymphoma. Am J Surg Pathol. 2007 Jan; 31(1):106-12. PMID: 17197926.
    Citations: 15     Fields:    Translation:HumansCells
  85. Shipp MA. Molecular signatures define new rational treatment targets in large B-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2007; 265-9. PMID: 18024639.
    Citations: 3     Fields:    Translation:Humans
  86. Rodig SJ, Abramson JS, Pinkus GS, Treon SP, Dorfman DM, Dong HY, Shipp MA, Kutok JL. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res. 2006 Dec 01; 12(23):7174-9. PMID: 17145843.
    Citations: 34     Fields:    Translation:Humans
  87. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006 Nov 15; 108(10):3428-33. PMID: 16888096.
    Citations: 37     Fields:    Translation:HumansCells
  88. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA. BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Mol Cell Biol. 2006 Jul; 26(14):5348-59. PMID: 16809771.
    Citations: 33     Fields:    Translation:HumansCells
  89. Takahashi H, Feuerhake F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC, Shipp MA. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 1):3265-71. PMID: 16740746.
    Citations: 11     Fields:    Translation:HumansCells
  90. Pasqualucci L, Compagno M, Houldsworth J, Monti S, Grunn A, Nandula SV, Aster JC, Murty VV, Shipp MA, Dalla-Favera R. Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med. 2006 Feb 20; 203(2):311-7. PMID: 16492805.
    Citations: 116     Fields:    Translation:HumansCells
  91. Shipp M. New concepts in treatment approaches and prognostic factors in aggressive NHL. Clin Adv Hematol Oncol. 2006 Feb; 4(2):107-9. PMID: 16728917.
    Citations: 1     Fields:    Translation:Humans
  92. Takahashi H, Feuerhake F, Monti S, Kutok JL, Aster JC, Shipp MA. Lack of IKBA coding region mutations in primary mediastinal large B-cell lymphoma and the host response subtype of diffuse large B-cell lymphoma. Blood. 2006 Jan 15; 107(2):844-5. PMID: 16401828.
    Citations: 3     Fields:    Translation:Humans
  93. Aguiar RC, Takeyama K, He C, Kreinbrink K, Shipp MA. B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J Biol Chem. 2005 Oct 07; 280(40):33756-65. PMID: 16061477.
    Citations: 51     Fields:    Translation:HumansCells
  94. Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA. NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. Blood. 2005 Aug 15; 106(4):1392-9. PMID: 15870177.
    Citations: 66     Fields:    Translation:HumansCells
  95. Goffin JR, Anderson IC, Supko JG, Eder JP, Shapiro GI, Lynch TJ, Shipp M, Johnson BE, Skarin AT. Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3417-24. PMID: 15867243.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  96. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood. 2005 Aug 15; 106(4):1164-74. PMID: 15855278.
    Citations: 55     Fields:    Translation:Humans
  97. Shipp MA, Aquino SL, Harris NL. Case records of the Massachusetts General Hospital. Case 12-2005. A 30-year-old woman with a mediastinal mass. N Engl J Med. 2005 Apr 21; 352(16):1697-704. PMID: 15843673.
    Citations: 1     Fields:    Translation:Humans
  98. Rodig SJ, Savage KJ, Nguyen V, Pinkus GS, Shipp MA, Aster JC, Kutok JL. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol. 2005 Feb; 29(2):196-203. PMID: 15644776.
    Citations: 13     Fields:    Translation:HumansCells
  99. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005 Mar 01; 105(5):1851-61. PMID: 15550490.
    Citations: 256     Fields:    Translation:HumansCells
  100. Louis K, Guérineau N, Fromigué O, Defamie V, Collazos A, Anglard P, Shipp MA, Auberger P, Joubert D, Mari B. Tumor cell-mediated induction of the stromal factor stromelysin-3 requires heterotypic cell contact-dependent activation of specific protein kinase C isoforms. J Biol Chem. 2005 Jan 14; 280(2):1272-83. PMID: 15509588.
    Citations: 5     Fields:    Translation:HumansCells
  101. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood. 2005 Jan 01; 105(1):308-16. PMID: 15331441.
    Citations: 45     Fields:    Translation:HumansCells
  102. Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D, Shipp M. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004 Apr; 45(4):761-7. PMID: 15160953.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  103. Fromigué O, Louis K, Wu E, Belhacène N, Loubat A, Shipp M, Auberger P, Mari B. Active stromelysin-3 (MMP-11) increases MCF-7 survival in three-dimensional Matrigel culture via activation of p42/p44 MAP-kinase. Int J Cancer. 2003 Sep 01; 106(3):355-63. PMID: 12845673.
    Citations: 8     Fields:    Translation:HumansCells
  104. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003 Dec 01; 102(12):3871-9. PMID: 12933571.
    Citations: 181     Fields:    Translation:HumansCells
  105. Wilkinson K, Velloso ER, Lopes LF, Lee C, Aster JC, Shipp MA, Aguiar RC. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003 Dec 01; 102(12):4187-90. PMID: 12907457.
    Citations: 19     Fields:    Translation:HumansCells
  106. Green BL, Person S, Crowther M, Frison S, Shipp M, Lee P, Martin M. Demographic and geographic variations of oral health among African Americans based on NHANES III. Community Dent Health. 2003 Jun; 20(2):117-22. PMID: 12828273.
    Citations: 6     Fields:    Translation:Humans
  107. Takeyama K, Aguiar RC, Gu L, He C, Freeman GJ, Kutok JL, Aster JC, Shipp MA. The BAL-binding protein BBAP and related Deltex family members exhibit ubiquitin-protein isopeptide ligase activity. J Biol Chem. 2003 Jun 13; 278(24):21930-7. PMID: 12670957.
    Citations: 40     Fields:    Translation:HumansAnimalsCells
  108. Braziel RM, Shipp MA, Feldman AL, Espina V, Winters M, Jaffe ES, Petricoin EF, Liotta LA. Molecular diagnostics. Hematology Am Soc Hematol Educ Program. 2003; 279-93. PMID: 14633786.
    Citations: 4     Fields:    Translation:Humans
  109. Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. Leuk Lymphoma. 2002 Apr; 43(4):793-7. PMID: 12153166.
    Citations: 22     Fields:    Translation:Humans
  110. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol. 2002 Mar 01; 20(5):1288-94. PMID: 11870171.
    Citations: 72     Fields:    Translation:HumansCTClinical Trials
  111. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002 Jan; 8(1):68-74. PMID: 11786909.
    Citations: 429     Fields:    Translation:HumansCTClinical Trials
  112. de Leval L, Ferry JA, Falini B, Shipp M, Harris NL. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol. 2001 Oct; 25(10):1277-82. PMID: 11688462.
    Citations: 15     Fields:    Translation:Humans
  113. Wu E, Mari BP, Wang F, Anderson IC, Sunday ME, Shipp MA. Stromelysin-3 suppresses tumor cell apoptosis in a murine model. J Cell Biochem. 2001; 82(4):549-55. PMID: 11500932.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  114. Loeffler M, Shipp M, Stein H. 2. Report on the workshop: "Clinical consequences of pathology and prognostic factors in aggressive NHL". Ann Hematol. 2001; 80 Suppl 3:B8-12. PMID: 11757715.
    Citations: 2     Fields:    Translation:Humans
  115. Shen R, Sumitomo M, Dai J, Hardy DO, Navarro D, Usmani B, Papandreou CN, Hersh LB, Shipp MA, Freedman LP, Nanus DM. Identification and characterization of two androgen response regions in the human neutral endopeptidase gene. Mol Cell Endocrinol. 2000 Dec 22; 170(1-2):131-42. PMID: 11162897.
    Citations: 18     Fields:    Translation:HumansCells
  116. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood. 2000 Dec 15; 96(13):4328-34. PMID: 11110709.
    Citations: 34     Fields:    Translation:HumansCells
  117. Anderson IC, Mari SE, Broderick RJ, Mari BP, Shipp MA. The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res. 2000 Jan 15; 60(2):269-72. PMID: 10667574.
    Citations: 14     Fields:    Translation:HumansCells
  118. Aguiar RC, Yakushijin Y, Kharbanda S, Tiwari S, Freeman GJ, Shipp MA. PTPROt: an alternatively spliced and developmentally regulated B-lymphoid phosphatase that promotes G0/G1 arrest. Blood. 1999 Oct 01; 94(7):2403-13. PMID: 10498613.
    Citations: 26     Fields:    Translation:HumansCells
  119. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999 Apr; 17(4):1244. PMID: 10561185.
    Citations: 762     Fields:    Translation:Humans
  120. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Coiffier B, Philip T. International Consensus Conference on high-dose therapy with hematopoietic stem-cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. Ann Oncol. 1999 Jan; 10(1):13-9. PMID: 10076716.
    Citations: 3     Fields:    Translation:Humans
  121. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol. 1999 Jan; 17(1):423-9. PMID: 10458261.
    Citations: 26     Fields:    Translation:Humans
  122. Howard OM, Shipp MA. The cellular and molecular heterogeneity of the aggressive non-Hodgkin's lymphomas. Curr Opin Oncol. 1998 Sep; 10(5):385-91. PMID: 9800106.
    Citations: 1     Fields:    Translation:Humans
  123. Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W, Anderson I, Shipp MA. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-Hodgkin's lymphoma. Blood. 1998 Jun 01; 91(11):4282-91. PMID: 9596677.
    Citations: 3     Fields:    Translation:AnimalsCells
  124. Mari BP, Anderson IC, Mari SE, Ning Y, Lutz Y, Kobzik L, Shipp MA. Stromelysin-3 is induced in tumor/stroma cocultures and inactivated via a tumor-specific and basic fibroblast growth factor-dependent mechanism. J Biol Chem. 1998 Jan 02; 273(1):618-26. PMID: 9417124.
    Citations: 11     Fields:    Translation:HumansCells
  125. Ishimaru F, Mari B, Shipp MA. The type 2 CD10/neutral endopeptidase 24.11 promoter: functional characterization and tissue-specific regulation by CBF/NF-Y isoforms. Blood. 1997 Jun 01; 89(11):4136-45. PMID: 9166856.
    Citations: 6     Fields:    Translation:HumansCells
  126. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol. 1997 Apr; 15(4):1631-7. PMID: 9193363.
    Citations: 10     Fields:    Translation:Humans
  127. Shipp MA. Can we improve upon the International Index? Ann Oncol. 1997; 8 Suppl 1:43-7. PMID: 9187428.
    Citations: 3     Fields:    Translation:Humans
  128. Ganju RK, Shpektor RG, Brenner DG, Shipp MA. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood. 1996 Dec 01; 88(11):4159-65. PMID: 8943850.
    Citations: 9     Fields:    Translation:HumansAnimalsCells
  129. Anderson IC, Shipp MA, Docherty AJ, Teicher BA. Combination therapy including a gelatinase inhibitor and cytotoxic agent reduces local invasion and metastasis of murine Lewis lung carcinoma. Cancer Res. 1996 Feb 15; 56(4):715-8. PMID: 8631001.
    Citations: 16     Fields:    Translation:Animals
  130. Ishimaru F, Potter NS, Shipp MA. Phorbol ester-mediated regulation of CD10/neutral endopeptidase transcripts in acute lymphoblastic leukemias. Exp Hematol. 1996 Jan; 24(1):43-8. PMID: 8536791.
    Citations: 2     Fields:    Translation:HumansCells
  131. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995 Dec; 13(12):2916-23. PMID: 8523055.
    Citations: 11     Fields:    Translation:HumansCells
  132. Anderson IC, Sugarbaker DJ, Ganju RK, Tsarwhas DG, Richards WG, Sunday M, Kobzik L, Shipp MA. Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. Cancer Res. 1995 Sep 15; 55(18):4120-6. PMID: 7664289.
    Citations: 13     Fields:    Translation:HumansCells
  133. Drazen JM, Evans JF, Stevens RL, Shipp MA. Inflammatory effector mechanisms in asthma. Am J Respir Crit Care Med. 1995 Jul; 152(1):403-7. PMID: 7599856.
    Citations:    Fields:    Translation:HumansCells
  134. Ishimaru F, Shipp MA. Analysis of the human CD10/neutral endopeptidase 24.11 promoter region: two separate regulatory elements. Blood. 1995 Jun 01; 85(11):3199-207. PMID: 7756651.
    Citations: 11     Fields:    Translation:HumansCells
  135. Ganju RK, Sunday M, Tsarwhas DG, Card A, Shipp MA. CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. J Clin Invest. 1994 Nov; 94(5):1784-91. PMID: 7962523.
    Citations: 7     Fields:    Translation:HumansCells
  136. Rohatiner A, d'Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, Lister TA, Norton A, Salem P, Shipp M, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994 May; 5(5):397-400. PMID: 8075046.
    Citations: 118     Fields:    Translation:Humans
  137. Shipp MA. Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood. 1994 Mar 01; 83(5):1165-73. PMID: 8118021.
    Citations: 28     Fields:    Translation:Humans
  138. Salles G, Shipp MA, Coiffier B. Chemotherapy of non-Hodgkin's aggressive lymphomas. Semin Hematol. 1994 Jan; 31(1):46-69. PMID: 8122135.
    Citations: 4     Fields:    Translation:Humans
  139. Salles G, Zain M, Jiang WM, Boussiotis VA, Shipp MA. Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies. Blood. 1993 Dec 15; 82(12):3539-47. PMID: 7505117.
    Citations: 15     Fields:    Translation:HumansCells
  140. Salles G, Rodewald HR, Chin BS, Reinherz EL, Shipp MA. Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo. Proc Natl Acad Sci U S A. 1993 Aug 15; 90(16):7618-22. PMID: 8356064.
    Citations: 5     Fields:    Translation:AnimalsCells
  141. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key! Blood. 1993 Aug 15; 82(4):1052-70. PMID: 8102558.
    Citations: 67     Fields:    Translation:HumansAnimalsCells
  142. Kirn D, Mauch P, Shaffer K, Pinkus G, Shipp MA, Kaplan WD, Tung N, Wheeler C, Beard CJ, Canellos GP, et al. Large-cell and immunoblastic lymphoma of the mediastinum: prognostic features and treatment outcome in 57 patients. J Clin Oncol. 1993 Jul; 11(7):1336-43. PMID: 8315431.
    Citations: 12     Fields:    Translation:Humans
  143. King KA, Hua J, Torday JS, Drazen JM, Graham SA, Shipp MA, Sunday ME. CD10/neutral endopeptidase 24.11 regulates fetal lung growth and maturation in utero by potentiating endogenous bombesin-like peptides. J Clin Invest. 1993 May; 91(5):1969-73. PMID: 8486767.
    Citations: 14     Fields:    Translation:AnimalsCells
  144. Heagy W, Shipp MA, Finberg RW. Opioid receptor agonists and Ca2+ modulation in human B cell lines. J Immunol. 1992 Dec 15; 149(12):4074-81. PMID: 1334111.
    Citations: 4     Fields:    Translation:HumansCells
  145. Sunday ME, Hua J, Torday JS, Reyes B, Shipp MA. CD10/neutral endopeptidase 24.11 in developing human fetal lung. Patterns of expression and modulation of peptide-mediated proliferation. J Clin Invest. 1992 Dec; 90(6):2517-25. PMID: 1469102.
    Citations: 17     Fields:    Translation:Humans
  146. Salles G, Chen CY, Reinherz EL, Shipp MA. CD10/NEP is expressed on Thy-1low B220+ murine B-cell progenitors and functions to regulate stromal cell-dependent lymphopoiesis. Blood. 1992 Oct 15; 80(8):2021-9. PMID: 1382716.
    Citations: 9     Fields:    Translation:AnimalsCells
  147. Shipp M. Prognostic factors in non-Hodgkin's lymphoma. Curr Opin Oncol. 1992 Oct; 4(5):856-62. PMID: 1457500.
    Citations: 1     Fields:    Translation:Humans
  148. Chen CY, Salles G, Seldin MF, Kister AE, Reinherz EL, Shipp MA. Murine common acute lymphoblastic leukemia antigen (CD10 neutral endopeptidase 24.11). Molecular characterization, chromosomal localization, and modeling of the active site. J Immunol. 1992 May 01; 148(9):2817-25. PMID: 1374101.
    Citations: 9     Fields:    Translation:AnimalsCells
  149. Shipp MA, Tarr GE, Chen CY, Switzer SN, Hersh LB, Stein H, Sunday ME, Reinherz EL. CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. Proc Natl Acad Sci U S A. 1991 Dec 01; 88(23):10662-6. PMID: 1660144.
    Citations: 43     Fields:    Translation:HumansCells
  150. Shipp MA, Stefano GB, Switzer SN, Griffin JD, Reinherz EL. CD10 (CALLA)/neutral endopeptidase 24.11 modulates inflammatory peptide-induced changes in neutrophil morphology, migration, and adhesion proteins and is itself regulated by neutrophil activation. Blood. 1991 Oct 01; 78(7):1834-41. PMID: 1717072.
    Citations: 31     Fields:    Translation:HumansCells
  151. Shapiro CL, Yeap BY, Godleski J, Jochelson MS, Shipp MA, Skarin AT, Canellos GP. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer. 1991 Aug 15; 68(4):699-705. PMID: 1713121.
    Citations: 6     Fields:    Translation:Humans
  152. Weeks JC, Yeap BY, Canellos GP, Shipp MA. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol. 1991 Jul; 9(7):1196-203. PMID: 1710656.
    Citations: 15     Fields:    Translation:Humans
  153. Stefano GB, Shipp MA, Scharrer B. A possible immunoregulatory function for [Met]-enkephalin-Arg6-Phe7 involving human and invertebrate granulocytes. J Neuroimmunol. 1991 Feb; 31(2):97-103. PMID: 1991823.
    Citations: 4     Fields:    Translation:HumansAnimalsCells
  154. Coiffier B, Shipp MA, Cabanillas F, Crowther D, Armitage JO, Canellos GP. Report of the first workshop on prognostic factors in large-cell lymphomas. Ann Oncol. 1991 Feb; 2 Suppl 2:213-7. PMID: 1675583.
    Citations: 2     Fields:    Translation:Humans
  155. Shipp MA, Stefano GB, D'Adamio L, Switzer SN, Howard FD, Sinisterra J, Scharrer B, Reinherz EL. Downregulation of enkephalin-mediated inflammatory responses by CD10/neutral endopeptidase 24.11. Nature. 1990 Sep 27; 347(6291):394-6. PMID: 1699130.
    Citations: 29     Fields:    Translation:HumansAnimalsCells
  156. Hughes TK, Smith EM, Chin R, Cadet P, Sinisterra J, Leung MK, Shipp MA, Scharrer B, Stefano GB. Interaction of immunoactive monokines (interleukin 1 and tumor necrosis factor) in the bivalve mollusc Mytilus edulis. Proc Natl Acad Sci U S A. 1990 Jun; 87(12):4426-9. PMID: 2352927.
    Citations: 18     Fields:    Translation:Animals
  157. Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, Rosenthal DS, Skarin AT, Canellos GP. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen. J Clin Oncol. 1990 Jan; 8(1):84-93. PMID: 1688615.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  158. D'Adamio L, Shipp MA, Masteller EL, Reinherz EL. Organization of the gene encoding common acute lymphoblastic leukemia antigen (neutral endopeptidase 24.11): multiple miniexons and separate 5' untranslated regions. Proc Natl Acad Sci U S A. 1989 Sep; 86(18):7103-7. PMID: 2528730.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
  159. Shipp MA, Klatt MM, Yeap B, Jochelson MS, Mauch PM, Rosenthal DS, Skarin AT, Canellos GP. Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy. J Clin Oncol. 1989 May; 7(5):613-8. PMID: 2468746.
    Citations: 4     Fields:    Translation:Humans
  160. Barker PE, Shipp MA, D'Adamio L, Masteller EL, Reinherz EL. The common acute lymphoblastic leukemia antigen gene maps to chromosomal region 3 (q21-q27). J Immunol. 1989 Jan 01; 142(1):283-7. PMID: 2521237.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  161. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U S A. 1989 Jan; 86(1):297-301. PMID: 2521388.
    Citations: 46     Fields:    Translation:HumansAnimalsCells
  162. Ernst TJ, Gazdar A, Ritz J, Shipp MA. Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood. 1988 Oct; 72(4):1163-7. PMID: 3048435.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  163. Shipp MA, Richardson NE, Sayre PH, Brown NR, Masteller EL, Clayton LK, Ritz J, Reinherz EL. Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4819-23. PMID: 2968607.
    Citations: 33     Fields:    Translation:HumansCells
  164. Tantravahi R, Shipp MA, Greeley TA, Pavelka K, Bern MM, Rosenthal DS, Frei E. Four patients with myelodysplastic syndrome with translocation (1;7)(p11;p11) including one patient with independent clones del(7)q22) [corrected] and t(1;7)(q21;q11) Cancer Genet Cytogenet. 1988 Jan; 30(1):83-90. PMID: 3422049.
    Citations:    Fields:    Translation:HumansCells
  165. Shipp MA, Reinherz EL. Differential expression of nuclear proto-oncogenes in T cells triggered with mitogenic and nonmitogenic T3 and T11 activation signals. J Immunol. 1987 Oct 01; 139(7):2143-8. PMID: 2821108.
    Citations: 14     Fields:    Translation:HumansCells
  166. Canellos GP, Skarin AT, Klatt MM, Rosenthal DS, Case DC, Pinkus GS, Jochelson MS, Yeap BY, Shipp MA. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol. 1987 Apr; 24(2 Suppl 1):2-7. PMID: 2438777.
    Citations: 3     Fields:    Translation:Humans
  167. Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, Rosenthal DS, Skarin AT, Canellos GP. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986 Jun; 104(6):757-65. PMID: 2422995.
    Citations: 21     Fields:    Translation:HumansCells
  168. Douglass EC, Green AA, Wrenn E, Champion J, Shipp M, Pratt CB. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol. 1985; 13(4):187-90. PMID: 2989669.
    Citations: 16     Fields:    Translation:Humans
  169. Shipp MA, Takvorian RC, Canellos GP. High-dose cytosine arabinoside. Active agent in treatment of non-Hodgkin's lymphoma. Am J Med. 1984 Nov; 77(5):845-50. PMID: 6496539.
    Citations: 1     Fields:    Translation:Humans
  170. Shipp MA, Schwartz BD, Kannapell CC, Griffith RC, Scott MG, Ahmed P, Davie JM, Nahm MH. A unique DR-related B cell differentiation antigen. J Immunol. 1983 Nov; 131(5):2458-67. PMID: 6415171.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Shipp's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (699)
Explore
_
Co-Authors (124)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.